Galera KOL Hour: Mitigating Kidney Damage in Platinum-Based Cancer Treatments
Virtual,
May 22, 2020
Please join us for a discussion on the effects of toxicity in cancer medicine and how new advances in medicine could potentially afford better quality of life and reduce lifelong burden of care for patients. Webcast available at the link below or via the events page in the investors section of Galera's website, www.galeratx.com.
Audience Q&A will immediately follow the interview.

Galera Therapeutics
[GRTX]
US$271 MM MCap
Clinical stage biopharmaceutical company focusing on transforming radiotherapy in cancer. Lead asset GC4419 is a potent, highly selective small molecule dismutase mimetic being developed for severe oral mucositis, currently in Phase 3 with Breakthrough Therapy Designation. Topline results expected in 1H21. Top line results in Phase 1b/2a in second asset, GC4419 in pancreatic cancer expected in 2H20. GC4419 expected to initiate in Phase 1b/2a in lung cancer in 2H20. [more information]